Impact of PCSK9 Inhibitors on Lipoprotein(a): A Meta-analysis and Meta-regression of Randomized Controlled Trials

Frederick Berro Rivera, MD;^a Sung Whoy Cha, MD;^b John Vincent Magalong, MD;^c Vincent Anthony Tang, MD;^c Mary Grace Enriquez, MD;^c Martha Gulati, MD MS;^d Byambaa Enkhmaa, MD, PhD^e; Neha Pagidipati, MD, MPH;^f Nishant P. Shah, MD^f

^aLincoln Medical Center, Bronx, New York (NY), USA
^bCebu Institute of Medicine, Cebu City, Philippines
^cUniversity of the Philippines, College of Medicine, Manila, Philippines
^dDepartment of Cardiology, Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA.
^eDivision of Endocrinology, Diabetes & Metabolism, UC Davis Health, Davis, CA, USA
^fDivision of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA.

Running title: PCSK9 inhibitors significantly reduced Lp(a): A meta-regression

Address for correspondence:

Frederick Berro Rivera, MD Department of Medicine, Lincoln Medical Center 234E 149th St., The Bronx, New York, USA, 10451 Email address: <u>frederick.berro.rivera@gmail.com</u> Contact number: 929-8559083 Twitter handle: @FredRiveraMD

Total word count: 3,298

ABSTRACT

Background: Lipoprotein(a) [Lp(a)] has been independently associated with increased cardiovascular risk. We examined the effect of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) on plasma Lp(a) levels across multiple clinical trials.

Methods: Studies were retrieved comparing the effect of PCSK9i vs. placebo on Lp(a) levels. The primary outcome was percent change in Lp(a) levels. Secondary outcomes included percent change in additional cholesterol markers. Factors associated with the treatment effect were determined by meta-regression analysis. Subgroup analyses were done to explore potential treatment effect differences based on comparator, PCSK9i type, treatment duration, and presence of familial hypercholesterolemia (FH).

Results: 47 studies with 67,057 patients were analyzed. PCSK9i reduced Lp(a) levels on average of -27% (95% CI: -29.8 to -24.1, p<0.001). Concurrent reduction in LDL-C, non-HDL-C, total cholesterol, triglycerides ApoB, ApoA-1, and increased HDL-C were also observed with PCSK9i use. Factors associated with the treatment effect included mean percent change in LDL-C (p=0.02, tau²=177.1, R²=0.00) and Apo-B (p<0.00, tau²=114.20, R²=1.42). Subgroup analyses revealed consistent treatment effect amongst comparators (vs. placebo: -27.69% (95% CI: -30.85 to -24.54, p<0.00), vs. ezetimibe: -24.0% (95% CI: -29.95% to -18.01, p<0.00), type of PCSK9i, evolocumab: -29.35% (95% CI: -33.56 to -25.14, p<0.00) vs. alirocumab: -24.50% (95% CI: -27.96 to -21.04, p<0.00), and presence of FH: -25.63% (95% CI: -31.96% to -19.30, p<0.00 vs. no FH: -27.22% (95% CI: -30.34. to -24.09, p<0.00). Varying treatment effects were noted in the duration of treatment (12 weeks or shorter: -32.43% (95% CI: -36.63 to -28.23 vs. >12 weeks: -22.31% (95% CI: -25.13 to -19.49, p<0.00), p interaction <0.01.

Conclusion: PCSK9 inhibitors reduce Lp(a) levels by an average of 27%. Mean percent change in LDL-C and Apo-B were associated with treatment effect. PCSK9i also significantly reduced other atherogenic lipoproteins. Across multiple clinical trials, PCSK9i has a consistent effect of significantly lowering Lp(a) levels.

Keywords: Lp(a), atherosclerotic cardiovascular disease, PCSK9 inhibitors, Alirocumab, Evolocumab, cholesterol, low density lipoprotein, apolipoprotein B

Abbreviations

ApoA1 = apolipoprotein A1 ApoB = apolipoprotein B CHD = coronary heart disease CVD = cardiovascular disease FH = familial hypercholesterolemia HDL = high-density lipoprotein LDL-C = low-density lipoprotein cholesterol Lp(a) = lipoprotein(a) MACE = major adverse cardiovascular events MI = myocardial infarction non-HDL-C = non-high-density lipoprotein cholesterol PAD = peripheral arterial disease PCSK9 = proprotein convertase subtilisin/kexin type 9 RCTs = randomized controlled trials

INTRODUCTION

Lipoprotein(a) [Lp(a)] is associated with premature and aggressive atherosclerosis across multiple vascular beds (1, 2), along with an increased risk of cardiovascular events.($\underline{3}$, $\underline{4}$) Plasma Lp(a) level is genetically determined and elevated in 20% of the general population.($\underline{5}$) Levels >50 mg/dL (or >125 nmol/L) are associated with significantly increased cardiovascular risk, independent of LDL-cholesterol (LDL-C) level, and therefore Lp(a) is considered a risk enhancer in ACC/AHA and ESC/EAS guidelines.($\underline{5}$, $\underline{6}$) Furthermore, a 3.5 fold higher Lp(a) levels increases the risk of death from cardiovascular disease (CVD), myocardial infarction (MI), and urgent coronary revascularization by 16%.(7) ($\underline{8}$)

Proprotein convertase subtilisin /kexin type 9 (PCSK9) inhibitors (PCSK9i) have been postulated to lower Lp(a) level by reducing its production and enhancing clearance.(9) Patients who have higher baseline plasma Lp(a) level tend to experience greater Lp(a) lowering with PCSK9i therapy, which is associated with fewer adverse coronary events.(7) In a post-hoc analysis of the ODYSSEY Outcomes trial, reduction in Lp(a) by alirocumab contributed to a reduction in major adverse cardiovascular events (MACE), independent of LDL-C lowering.(10, 11). However, whether PCSK9i therapy lowers Lp(a) consistently across multiple studies is not well established.

Our meta-analysis aims to quantify the extent of Lp(a) reduction that can be achieved with PCSK9i therapy across multiple clinical trials, focusing on the monoclonal antibody variants like alirocumab and evolocumab. In addition to determining the percent reduction in Lp(a) by PCSK9i, we also aim to identify factors that influence the degree of Lp(a) lowering, as well as better understand the potential treatment effect differences based on PCSK9i type,

comparator, treatment duration, and presence of familial hypercholesterolemia (FH). Concurrent reduction in other atherogenic lipoproteins with PCSK9i use is also assessed.

METHODS

This study was reported under the Preferred Reporting Items for a Review and Meta-Analysis (PRISMA)(<u>12</u>), and the checklist(<u>13</u>) was followed (**see Supplementary Figure 1 and Supplementary Table 1**). Certainty of evidence was rated using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) framework.(<u>14</u>) This study was registered in the International Prospective Register of Systematic Reviews (PROSPERO)(<u>15</u>), with the identification number CRD42022378644.

Data Sources and Searches

The literature search was performed using PubMed/MEDLINE, Ovid/Embase, Web of Science, SCOPUS, and Cochrane databases from database inception until May 2024. Search terms included "PCSK9 inhibitor", "PCSK9 antibody", "Evolocumab", "Alirocumab", "Bococizumab", "AMG145", "Repatha", "REGN727", "SAR236553", "RN 316", "PF-04950615", "LY3015014", "RG7652", "Lipoprotein a", "Lp(a)", "randomized controlled trial", "randomization", "clinical trials", "intervention studies" and synonyms. PCSK9i therapies that are not monoclonal antibodies, such as inclisiran, were not included. Citations of selected articles and any relevant studies that evaluated Lp(a) and LDL-C lowering using PCSK9i were reviewed. After removing duplicates, records were reviewed at the title and abstract level, followed by the screening of full text based on our study criteria.

Study Selection

Eligible phase II or phase III, double-blind randomized controlled trials (RCTs) comparing treatment with monoclonal antibody PCSK9i with placebo and/or ezetimibe in adult patients aged 18 years and above were included. Moreover, the studies must have reported baseline Lp(a) level and Lp(a) reduction in mean percent change, and treatment duration had to be 8 weeks or longer. Additionally, mean percent change in LDL-C and Apo-B from the baseline must have been reported. Studies were excluded if (1) they did not report a control arm, (2) they reported absolute change, or (3) Lp(a) was reported as median instead of mean. Other agents such as bococizumab and inclisiran were excluded because cardiovascular outcomes are not well established with these agents. We also excluded RCTs with participants younger than 18, and those reporting interim or post hoc analysis. Cross-over trials were also excluded due to the nature of the outcomes considered. Review articles, case reports, letters to the editor, commentaries, proceedings, laboratory studies, and other non-relevant studies were excluded as well.

Data Extraction

Key participant and intervention characteristics and reported data on efficacy outcomes were extracted independently by two investigators (JM and VT) using standard data extraction templates. Any disagreements were resolved by discussion or, if required, by a third author (FBR). Data on the following variables were extracted: first author's name, year of publication, journal, study phase, interventional and control treatments, randomization method, analysis tool, number of randomized patients, and demographic and clinical data (e.g., age, sex). In case of uncertainties regarding the study data, we contacted the authors of the specific study for

additional information. Quality assessment was performed independently by two review authors (JM and VT) using the Revised Cochrane risk-of-bias tool for randomized trials.

Outcome Measures

The primary endpoint of this meta-analysis and meta-regression was percent change from baseline in Lp(a) levels. Secondary endpoints included mean percent change from baseline in LDL-C, non-high-density lipoprotein cholesterol (HDL-C), total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), apolipoprotein B (Apo-B), and apolipoprotein A1 (Apo-A1). Additionally, subgroup analyses were performed for applicable studies on the (1) type of PCSK9i, (2) comparator (placebo versus ezetimibe), (3) duration of treatment, and (4) population (FH versus no FH).

Bias Assessment

All included studies reported a central randomization process, and outcomes were objectively determined. The included studies reported all primary and secondary outcomes as pre-specified in their protocols, so the risk of bias for selective reporting was judged as low. Two authors (JM and VT) independently assessed the risk of bias based on the Cochrane Risk of Bias Tool (**Supplementary Figures 2a and 2b**) for studies that fulfilled the inclusion criteria. Disagreements between the two reviewers were resolved by consensus. In case of persistent disagreement, arbitration by a third reviewer (FBR) was performed.

Statistical Analysis

medRxiv preprint doi: https://doi.org/10.1101/2024.07.10.24310245; this version posted July 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Stata Statistical Software version 18, College Station, TX: StataCorp LLC was used to conduct the included studies' meta-analysis, heterogeneity tests, and sensitivity analyses. For all outcomes, the significance level was set at a p-value of <0.05. Statistical heterogeneity was identified through the forest plots and a standard Chi-squared test with a significant level of p<0.1. The extent of heterogeneity was based on the I² statistic, wherein a value of more than 50% was interpreted as substantial heterogeneity. We pooled all estimates using a random effects model. Effect sizes were expressed using mean differences with 95% confidence intervals (CIs). Prespecified subgroup analyses were performed according to the (1) type of PCSK9i, (2) comparator (placebo versus ezetimibe), (3) duration of treatment, and (4) population (FH versus no FH). Regression analyses were performed to determine baseline factors such as LDL-C and Apo-B levels that could affect the point estimate. Changes in mean LDL-C was incorporated as possible covariate because of the reported higher discordance in LDL-C reduction for higher Lp(a) levels.(16) and Apo-B was incorporated in regression analysis as studies have suggested that it is not always linked on a single Lp(a) particle.(9)

RESULTS

A literature search through July 2023, yielded 2,328 potentially relevant references on PCSK9i therapy, focusing on monoclonal antibody-based therapies (**Supplementary Figure 1**). Of these, 33 duplicates were removed. A total of 2,152 studies with unrelated interventions, outcomes, populations, non-original data (e.g., meta-analysis or review), descriptive or observational study design and study protocols were excluded. A total of 114 studies were left, and 35 pooled analyses were removed for not meeting the eligibility criteria. The remaining 79 related studies were included

in the final meta-analysis. From the 47 studies, data from 67,057 eligible individuals were included for analysis. The study characteristics are shown in **Table 1**.

Lp(a) reduction

PCSK9i significantly reduced Lp(a) levels by -27% (95% CI: -29.8 to -24.1, p<0.00) on average compared with its comparator (placebo or ezetimibe). Significant heterogeneity was noted between the study results (I^2 96.16; p<0.00) (**Figure 1**), which could be explained by the differences in patient risk profile and population characteristics (i.e., comorbidity like FH, race), type of PCSK9i, and treatment duration among others.

Subgroup analyses

PCSK9i significantly reduced Lp(a) by -28% when compared to placebo mean difference (MD) - 27.69% (95% CI: -30.85 to -24.54), p<0.00], and -24% when compared to ezetimibe [MD - 24.0% (95% CI: -29.95% to -18.01), p<0.00]. There was no significant difference in the treatment effect of PCSK9i compared with ezetimibe or placebo (p interaction 0.25) (**Figure 2**). The treatment effects of alirocumab and evolocumab on Lp(a) lowering were not significantly different (p interaction 0.06) (**Figure S3**). The achieved Lp(a) reduction by PCSK9i use was significantly different between those who had received treatment for equal to and less than 12 weeks [-32.43% (95% CI: -36.63 to -28.23)] vs. those who received treatment for more than 12 weeks [-22.31% (95% CI: -25.13 to -19.49, p<0.00)] (p interaction <0.01) (**Figure S4**). PCSK9i reduced Lp(a) for both FH and non-FH cohorts. (**Figure S5**)

Meta-regression analysis

Meta-regression analysis revealed that the mean change of LDL-C (p=0.02, tau²=177.10, R² analog=0.00) and Apo-B (p<0.001, tau²=114.20, R=1.42) were associated with the effect size difference (**Figures 3 and 4**). Baseline LDL-C (p=0.14, Q=2.17, R² analog= 0.00) and baseline mean age (p=0.43, Q=0.63, R² analog=0.00) were not associated with the treatment effect.

Effects of PCSK9 inhibitors on other lipid markers

PCSK9i reduced LDL-C by -52.41% [(95% CI -55.28 to -49.54%), p<0.01]. PCSK9i also reduced non-HDL-C by -46.48%, TC by -34.42%, triglycerides by -11.11%, and Apo-B by 43.16%. PCSK9i increased ApoA-1 by 4.44% and HDL-C by 5.98% (**Figures S6-12**). **Table 2** shows the summary results on the effects of PCSK9i on other lipid markers.

DISCUSSION

In this meta-analysis of the impact of PCSK9i on Lp(a) level, we found that PCSK9i significantly reduced Lp(a) level regardless of comparator (placebo or ezetimibe), duration of treatment, type of PCSK9i, or presence of FH. Additionally, the mean percent change from baseline of LDL-C and Apo-B were associated with treatment indicating that the degree of Lp(a) lowering by PCSK9i depended on how much LDL-C and Apo-B were lowered. (**Central Illustration**)

Among the subgroups analyses, only the difference in duration of treatment had significant bearing on the treatment effect. Although our study demonstrated that PCSK9i leads to a modest Lp(a) lowering, the treatment effect appears to be higher in the first 12 weeks vs beyond 12 weeks of treatment. Some potential mechanisms underlying this observation have been proposed. Prolonged use of PCSK9i may induce its own resistance, which is thought to be

from (1) increased endogenous PCSK9 triggered by PCSK9i use, and (2) delayed PCSK9 clearance due to accumulation of monoclonal antibody-PCSK9 complexes.(<u>17</u>) However, more data is needed to determine the possible reason of this treatment difference.

Many prospective studies have reported the role of PCSK9i in reducing Lp(a) levels(18), and prior pooled analyses have supported the efficacy of these agents. (19, 20) The results of our meta-analysis showed that the use of PCSK9i resulted in statistically significant reductions in plasma Lp(a) levels vs. comparators (placebo and ezetimibe), further increasing our understanding of the effect of PCSK9i on Lp(a) level based on data from multiple clinical trials. Furthermore, this analysis enriches available evidence by providing detailed information on subgroups of interest, based on duration of treatment, comparator, type of PCSK9i and presence of FH. The 27% reduction in Lp(a) level with PCSK9i compared to comparators (placebo and ezetimibe) in this analysis is consistent with the reports in previous meta-analyses citing on avergae26% reduction.(19, 20) Beyond confirming this PCSK9i's effect on Lp(a), we also performed robust subgroup analyses with emphasis on duration of treatment and FH status. Using meta-regression analysis, we were able to determine factors associated with the treatment effect such as percent change of LDL-C and Apo-B from baseline. Changes in mean LDL-C was incorporated as possible covariate because of the reported higher discordance in LDL-C reduction for higher Lp(a) levels. (16) Apo-B was incorporated in regression analysis as studies have suggested that it is not always linked on a single Lp(a) particle hence can affect Lp(a) levels after PCSK9i.(9)

In previous studies by Farmakis and Yu, an Lp(a) reduction between 25-35% led to a clinically significant coronary heart disease (CHD) risk reduction(<u>19</u>, <u>20</u>), and our data shows that monoclonal antibody based PCSK9i reduces Lp(a) level in the same range (-27%). Although

studies have shown that a higher degree of absolute Lp(a) lowering (at least 50 mg/dL or 105 nmol/L) may be needed for a significant CHD risk reduction.(21), data from ODYSSEY Outcomes trial subanalysis showed the contrary.(10) Even a 1 mg/dL reduction in Lp(a) was associated with a hazard ratio of 0.99 (95% CI 0.99 to 0.00; p=0.008).(10) Trials on cardiovascular outcomes with Lp(a) reduction using directly targeting Lp(a) therapies such as the Lp(a)HORIZON (NCT04023552) and OCEAN(a) Outcomes trial (NCT05581303) are still ongoing, but they have shown reductions in Lp(a) level in the range of 80–95%. Findings in these trials will help better understand the optimal absolute reduction in Lp(a) level needed for effective risk reduction.

Limitations

There are several limitations that should be noted. This is a study-level meta-analysis, and we could not access individual patient data. Additional limitations include heterogeneity in PCSK9i studies. While we attempted to explain potential reasons for the heterogeneity using subgroup analyses, the lack of disaggregated data precluded further analyses for the matter. Sex and race are important subgroups that were sought from the studies reviewed; unfortunately, our findings show a gross lack of sex disaggregated data to permit subgroup analyses. Future trials should explore these specific disaggregated variables to obtain a deeper understanding of how the treatment effect may vary among these subgroups. Publication bias may also be present, the extent of which could not fully be quantified. Nonetheless, every effort possible was made to limit bias by utilizing a robust analytical approach to adjust for potential moderators through subgroup analyses and meta-regression.

Conclusion

An elevated level of Lp(a) is an independent highly prevalent risk factor for atherosclerotic cardiovascular disease. In this analysis of 47 RCTs comparing PCSK9i monoclonal antibody therapy vs placebo or ezetimibe, PCSK9 inhibitors reduced Lp(a) levels by 27% on average. Mean change from the baseline in LDL-C and Apo-B positively correlates with Lp(a) reduction. Given the modest but significant reduction in Lp(a) level, further research is needed to evaluate the impact of monoclonal antibody based PCSK9i on cardiovascular outcomes in patients with elevated Lp(a).

Acknowledgement: None

Statement of Ethics: Ethics approval for this paper is not required because this study is based exclusively on published literature. Patient consent was not needed as this study was based on publicly available data.

Conflict of Interest Statement: MG: Consultant Fees/Honoraria: Esperion, Novartis, and Boehringer Ingelheim Research/Research Grants: Congressionally Directed Medical Research Program-Department of Defense (WARRIOR study). NP: Consulting/honoraria: Bayer, Boehringer Ingelheim, CRISPR Therapeutics, Eli Lilly, Esperion, AstraZeneca, Merck, Novartis, and Novo Nordisk.; Grants to institution: Alnylam, Amgen, Boehringer Ingelheim, Eggland's Best, Eli Lilly, Novartis, and Novo Nordisk, DSMB for trials sponsored by J+J and Novartis.

Funding Sources: This paper was not funded.

Author Contributions: Frederick Berro Rivera, MD, Sung Whoy Cha, MD, John Vincent Magalong, MD, Vincent Anthony Tang, MD, Mary Grace Enriquez, MD: **Data curation**; Frederick Berro Rivera, MD, John Vincent Magalong, MD: **Formal analysis**; Frederick Berro Rivera, MD, Sung Whoy Cha, MD, John Vincent Magalong, MD, Vincent Anthony Tang, MD, Mary Grace Enriquez, MD; **Investigation**; Frederick Berro Rivera, MD, Sung Whoy Cha, MD, John Vincent Magalong, MD, Vincent Anthony Tang, MD, Mary Grace Enriquez, MD: **Methodology**; Frederick Berro Rivera, MD, John Vincent Magalong, MD; **Validation**; Martha Gulati, MD MS; Byambaa Enkhmaa, MD, PhD; Neha Pagidipati, MD, MPH; Nishant P. Shah, MD: **Writing - original draft;** Frederick Berro Rivera, MD; Sung Whoy Cha, MD: **Writing -**

review & editing; Martha Gulati, MD MS; Byambaa Enkhmaa, MD, PhD; Neha Pagidipati, MD, MPH; Nishant P. Shah, MD

Data Availability Statement: All data generated or analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author.

Tables

Table 1. Characteristics of included studiesTable 2: Summary on the effects of PCSK9i on other lipids

Figures

Figure 1: Central Illustration

Figure 2: Forest plot on the effect on PCSK9i on lipoprotein a

Figure 3: Forest plot on the effect sizes on different prespecified subgroups

Figure 4: Scatter plot on the meta-regression analysis of mean changes in LDL-C (A) and Apo-

B (B) from intervention on mean change of Lp(a)

Supplementary materials

Supplementary figures

Figure S1: Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) flow diagram

Figure S2: Risk of bias assessment

Figure S3: Subgroup analysis on type of PCSK9i

Figure S4: Subgroup analysis on duration of treatment

Figure S5: Subgroup analysis on type of population

Figure S6: Subgroup analysis on race

Figure S7: Forest plot on LDL reduction

Figure S8: Forest plot on non-HDL C reduction

Figure S9: Forest plot on total cholesterol reduction

Figure S10: Forest plot on triglycerides reduction

Figure S11: Forest plot on Apo-B reduction

Figure S12: Forest plot on HDL-C reduction

Figures S13: Funnel plots showing the risk of bias on the effect of PCSK9i on Lp(a) (A), Low density Lipoprotein Cholesterol (B), High density Lipoprotein Cholesterol (C) and non-High density Lipoprotein Cholesterol (D), Total Cholesterol (E), Triglycerides (F), Apo-A1 (G), and Apo-B (H).

Supplementary table Table S1: PRISMA Checklist

REFERENCES:

1. Laschkolnig A, Kollerits B, Lamina C, Meisinger C, Rantner B, Stadler M, et al. Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts. Cardiovasc Res. 2014;103(1):28-36.

2. Gurdasani D, Sjouke B, Tsimikas S, Hovingh GK, Luben RN, Wainwright NW, et al. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol. 2012;32(12):3058-65.

3. Schmidt K, Noureen A, Kronenberg FA-O, Utermann G, Tsimikas S, Gencer B, et al. Structure, function, and genetics of lipoprotein (a)

A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies

Lipoprotein(a): the revenant

Lipoprotein(a) Gets Worse

Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies Lipoprotein(a). (1539-7262 (Electronic)).

4. Kostner KM, Kostner GM. Lipoprotein(a): still an enigma? Curr Opin Lipidol. 2002;13(4):391-6.

6. Reves-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48-e60.

7. O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019;139(12):1483-92.

8. Verwer MC, Waissi F, Mekke JM, Dekker M, Stroes ESG, de Borst GJ, et al. High lipoprotein(a) is associated with major adverse limb events after femoral artery endarterectomy. Atherosclerosis. 2022;349:196-203.

9. Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, et al. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans. Circulation. 2017;135(4):352-62.

10. Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. J Am Coll Cardiol. 2020;75(2):133-44.

11. Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, et al. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. J Am Coll Cardiol. 2021;78(5):421-33.

12. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71.

13. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj. 2009;339:b2700.

14. Schwingshackl L, Rüschemeyer G, Meerpohl JJ. [How to interpret the certainty of evidence based on GRADE (Grading of Recommendations, Assessment, Development and Evaluation)]. Urologe A. 2021;60(4):444-54.

15. Sideri S, Papageorgiou SN, Eliades T. Registration in the international prospective register of systematic reviews (PROSPERO) of systematic review protocols was associated with increased review quality. J Clin Epidemiol. 2018;100:103-10.

16. Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, Fazio S. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab. J Am Heart Assoc. 2019;8(4):e010932.

17. Shapiro MD, Miles J, Tavori H, Fazio S. Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor. Ann Intern Med. 2018;168(5):376-9.

18. Rhainds D, Brodeur MR, Tardif JC. Lipoprotein (a): When to Measure and How to Treat? Curr Atheroscler Rep. 2021;23(9):51.

19. Farmakis I, Doundoulakis I, Pagiantza A, Zafeiropoulos S, Antza C, Karvounis H, Giannakoulas G. Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis. J Cardiovasc Pharmacol. 2021;77(3):397-407.

20. Yu Z, Hu L, Sun C, Wang Z, Zhang X, Wu M, Liu L. Effect of Different Types and Dosages of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a) Levels: A Network Meta-analysis. J Cardiovasc Pharmacol. 2023;81(6):445-53.

21. Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG. Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study. Arterioscler Thromb Vasc Biol. 2020;40(1):255-66.

22. Ako J, Hibi K, Tsujita K, Hiro T, Morino Y, Kozuma K, et al. Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome — The ODYSSEY J-IVUS Trial —. Circulation Journal. 2019;83(10):2025-33.

23. Bays H, Gaudet D, Weiss R, Ruiz JL, Watts GF, Gouni-Berthold I, et al. Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. J Clin Endocrinol Metab. 2015;100(8):3140-8.

Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, et al. A 52-week
placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809-19.
Blom DJ, Harada-Shiba M, Rubba P, Gaudet D, Kastelein JJP, Charng MJ, et al.
Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia:

The ODYSSEY HoFH Trial. J Am Coll Cardiol. 2020;76(2):131-42.

26. Boccara F, Kumar PN, Caramelli B, Calmy A, López JAG, Bray S, et al. Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study. J Am Coll Cardiol. 2020;75(20):2570-84.

27. Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36(19):1186-94.

28. Chao TH, Hsiao PJ, Liu ME, Wu CJ, Chiang FT, Chen ZC, et al. A subanalysis of Taiwanese patients from ODYSSEY South Korea and Taiwan study evaluating the efficacy and safety of alirocumab. J Chin Med Assoc. 2019;82(4):265-71.

29. Farnier M, Jones P, Severance R, Averna M, Steinhagen-Thiessen E, Colhoun HM, et al. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. Atherosclerosis. 2016;244:138-46.

30. Ginsberg HN, Rader DJ, Raal FJ, Guyton JR, Baccara-Dinet MT, Lorenzato C, et al. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. Cardiovasc Drugs Ther. 2016;30(5):473-83.

31. Han Y, Chen J, Chopra VK, Zhang S, Su G, Ma C, et al. ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand. J Clin Lipidol. 2020;14(1):98-108.e8.

32. Hao Y, Yang YL, Wang YC, Li J. Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome. Int Heart J. 2022;63(4):669-77.

33. Hirayama A, Honarpour N, Yoshida M, Yamashita S, Huang F, Wasserman SM, Teramoto T. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study. Circ J. 2014;78(5):1073-82.

34. Janik MJ, Urbach DV, van Nieuwenhuizen E, Zhao J, Yellin O, Baccara-Dinet MT, et al. Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: A prospective, randomized, placebo-controlled study. Atherosclerosis. 2021;331:20-7.

35. Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996-3003.

36. Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am Heart J. 2015;169(6):906-15.e13.

37. Kiyosue A, Honarpour N, Kurtz C, Xue A, Wasserman SM, Hirayama A. A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk. Am J Cardiol. 2016;117(1):40-7.

38. Koh KK, Nam CW, Chao TH, Liu ME, Wu CJ, Kim DS, et al. A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT). J Clin Lipidol. 2018;12(1):162-72.e6.

39. Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380(9858):1995-2006.

40. Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2531-40.

41. Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, et al. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). J Am Coll Cardiol. 2019;74(20):2452-62.

42. Cariou B, Leiter LA, Müller-Wieland D, Bigot G, Colhoun HM, Del Prato S, et al. Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial. Diabetes Metab. 2017;43(5):453-9.

43. Lorenzatti AJ, Eliaschewitz FG, Chen Y, Fialkow J, Lu J, Baass A, et al. Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial. Clin Cardiol. 2018;41(9):1117-22.

44. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59(25):2344-53.

45. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758-69.

46. Nissen SE, Nicholls SJ. Results of the GLAGOV trial. CCJM. 2017;84(12 suppl 4):e1-e5.

47. Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, et al. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. Jama. 2016;315(15):1580-90.

48. Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126(20):2408-17.

49. Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331-40.

50. Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):341-50.

51. Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. Jama. 2014;311(18):1870-82.

52. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489-99.

53. Rosenson RS, Daviglus ML, Handelsman Y, Pozzilli P, Bays H, Monsalvo ML, et al. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study. Diabetologia. 2019;62(6):948-58.

54. Roth EM, McKenney JM, Hanotin Ć, Asset G, Štein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367(20):1891-900.

55. Roth EM, McKenney JM. ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. Future Cardiol. 2015;11(1):27-37.

56. Roth EM, Moriarty PM, Bergeron J, Langslet G, Manvelian G, Zhao J, et al. A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. Atherosclerosis. 2016;254:254-62.

57. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-22.

58. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-107.

59. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380(9836):29-36.

60. Stiekema LCA, Stroes ESG, Verweij SL, Kassahun H, Chen L, Wasserman SM, et al. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong lowdensity lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. Eur Heart J. 2019;40(33):2775-81.

61. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541-8.

62. Stroes E, Guyton JR, Lepor N, Civeira F, Gaudet D, Watts GF, et al. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. J Am Heart Assoc. 2016;5(9).

63. Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. Jama. 2012;308(23):2497-506.

64. Teramoto T, Kobayashi M, Tasaki H, Yagyu H, Higashikata T, Takagi Y, et al. Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not

Adequately Controlled With Statins - ODYSSEY JAPAN Randomized Controlled Trial. Circ J. 2016;80(9):1980-7.

65. Teramoto T, Kiyosue A, Ishigaki Y, Harada-Shiba M, Kawabata Y, Ozaki A, et al. Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON. J Cardiol. 2019;73(3):218-27.

66. Watts GF, Chan DC, Dent R, Somaratne R, Wasserman SM, Scott R, et al. Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism. Circulation. 2017;135(4):338-51.

Table 1. Characteristics of Included Studies

Author (Year) / Name of Trial	Phase	No. of patients	Population	Age, years	Baseline Lp(a), nmol/L	Baseline LDL-C, mg/dL	Drug (dose and frequency)	Duration of treatment	Comparator	Primary Outcome
Ako et al. 2019 / ODYSSEY J-IVUS TRIAL(<u>22</u>)	4	206	Patients with ACS and hypercholesterolemia	61.2 ± 10.9	(-)	96.8± 22.5	Alirocumab 75 mg/150 mg every 2 weeks	36 weeks	Atorvastatin ≥10 mg/day or rosuvastatin ≥5 mg/day	Percent change in normalized total atheroma volume from baseline to week 36
Bays et al. 2015 / ODYSSEY OPTIONS I(<u>23</u>)	3	355	Hypercholesterolemia on statin and high CV risk	$62.9 \\ \pm \\ 10.2$	72.6± 102.5	105.1 ± 34.1	Alirocumab 75 mg/150 mg every 2 weeks	24 weeks	Statin and/or ezetimibe	Percent change in LDL-C from baseline to week 24
Blom et al. 2014 / DESCARTES(<u>24</u>)	3	905	Hypercholesterolemia	56.2 ± 10.6	63.9± 93.6	104.1± 21.9	Evolocumab 420 mg every 4 weeks	52 weeks	Placebo and/or atorvastatin and/or ezetimibe	Percent change in LDL-C from baseline to week 52
Blom et al. 2020 / ODYSSEY HoFH Trial(<u>25</u>)	3	69	HoFH	43.4 ± 14.7	(-)	282.7 ± 161.9	Alirocumab 150 mg every 2 weeks	12 weeks	Placebo	Percent change in LDL-C from baseline to week 12
Boccara et al. 2020 / BEIJERINCK(<u>26</u>)	3	467	People living with HIV and hypercholesterolemia and/or mixed	56.4 ± 8.7	86.2± 124.4	133.3 +/- 40.1	Evolocumab 420 mg SC monthly	24 weeks	Placebo	Percent change in LDL-C from baseline to week

			dyslipidemia							24
Cannon et al. 2015 / ODYSSEY COMBO II(<u>27</u>)	3	720	Hypercholesterolemia on statin and high CV risk	61.6 ± 9.3	(-)	107 ± 34.8	Alirocumab 75 mg/150 mg every 2 weeks	104 weeks	Ezetimibe 10 mg/day	Percent change in LDL-C from baseline to week 24
Chao et al. 2019 / ODYSSEY KT- TW(<u>28</u>)	3	116	Taiwanese patients with hypercholesterolemia on statin and high CV risk	$60.7 \\ \pm 10.0$	(-)	102 ± 27	Alirocumab 75 mg/150 mg every 2 weeks	24 weeks	Placebo	Percent change in LDL-C from baseline to week 24
Farnier et al. 2015 / ODYSSEY OPTIONS II(<u>29</u>)	3	305	Hypercholesterolemia on statin and high CV risk	60.9 ± 10.3	86.8± 94.9	111.2 ± 38.8	Alirocumab 75 mg/150 mg every 2 weeks	24 weeks	Statin and/or ezetimibe	Percent change in LDL-C from baseline to week 24
Ginsberg et al. 2016 / ODYSSEY HIGH FH(<u>30</u>)	3	107	HeFH and LDL-C ≥ 160 mg/dL on statin	50.6 ± 13.3	55.1± 60	197.8 ± 53.4	Alirocumab 150 mg every 2 weeks	78 weeks	Placebo	Percent change in LDL-C from baseline to week 24
Han et al. 2019 / ODYSSEY EAST(<u>31</u>)	3	615	Hypercholesterolemia on statin and high CV risk	58.6 ± 10.8	71.6± 73.7	110.8 ± 48.9	Alirocumab 75 mg/150 mg every 2 weeks	24 weeks	Ezetimibe	Percent change in LDL-C from baseline to week 24
Hao et al. 2022(<u>32</u>)		136	Extremely high-risk ACS with LDL-C \geq 3.0 mmol/L on statin	62.2 ± 11.8	(-)	136.5± 19.4	Evolocumab 140 mg every 2 weeks	12 weeks	Atorvastatin 40 mg/day and ezetimibe 10 mg/day	Major adverse cardiovascular events

Hirayama et al. 2014 / YUKAWA(<u>33</u>)	2	310	Hypercholesterolemia on statin and high CV risk	60.8	40.8 ± 41.9	141.1± 21.3	Evolocumab 70 mg/140 mg every 2 weeks or 280 mg/420 mg every 4 weeks	12 weeks	Placebo	Percent change in LDL-C from baseline to week 12
Janik et al. 2021(<u>34</u>)	4	2176	HeFH or non-FH on statin and high CV risk	63 (40- 85)	(-)	118.8± 41.2	Alirocumab 75 mg/150 mg every 2 weeks	96 weeks	Placebo	Change in CANTAB cognitive domain SWMS z-score from baseline to Week 96
Kastelein et al. 2015 / ODYSSEY FH I(<u>35</u>)	3	486	HeFH	52 ± 12.7	104.5 ± 106.4	144.6 ± 3.2	Alirocumab 75 mg/150 mg every 2 weeks	78 weeks	Placebo	Percent change in LDL-C from baseline to week 24
Kastelein et al. 2015 / ODYSSEY FH II(<u>35</u>)	3	249	HeFH	53.2 ± 12.7	$\begin{array}{c} 105.7 \pm \\ 105 \end{array}$	134.4 ± 3.7	Alirocumab 75 mg/150 mg every 2 weeks	78 weeks	Placebo	Percent change in LDL-C from baseline to week 24
Kereiakes et al. 2015 / ODYSSEY COMBO I(<u>36</u>)	3	316	Hypercholesterolemia on statin and high CV risk	63 ± 9.3	82.9 ± 107.7	103.4 ± 31.6	Alirocumab 75 mg/150 mg every 2 weeks	52 weeks	Placebo	Percent change in LDL-C from baseline to week 24
Kiyosue et al. 2016 / YUKAWA-2(<u>37</u>)	3	404	Patients with hyperlipidemia or mixed dyslipidemia	61.5	33.7 ± 31.7	106 ± 31.8	Evolocumab 140mg every 2	12 weeks	Placebo	Percent change in LDL-C from baseline to week

			and high CV risk				weeks/ 420mg monthly			12
Koh et al. 2017 / ODYSSEY KT(<u>38</u>)	3	199	Hypercholesterolemia on statin and high CV risk	60.6 ± 9.7	59.7 ± 67.5	98.2± 26.5	Alirocumab 75 mg/150 mg every 2 weeks	24 weeks	Placebo	Percent change in LDL-C from baseline to week 24
Koren et al. 2012 / MENDEL(<u>39</u>)	2	411	Hypercholesterolemia and low CV risk	51.2	73.5± 79.1	142.3 ± 22.6	Evolocumab 70 mg/105 mg/140 mg every 2 weeks or 280 mg/350 mg/420 mg every 4 weeks	12 weeks	Placebo or ezetimibe	Percent change in LDL-C from baseline to week 12
Koren et al. 2014 / MENDEL-2(<u>40</u>)	3	615	Hypercholesterolemia and moderate CV risk	53.2 ± 12.2	37 ± 55.4	142.9 ± 22.7	Evolocumab 140 mg every 2 weeks or 420 mg every 4 weeks	12 weeks	Placebo and/or ezetimibe	Percent change in LDL-C from baseline to week 12
Koskinas et al. 2019 / EVOPACS(<u>41</u>)	3	308	ACS patients	60.7 ± 11.4	68.6± 89.3	$\frac{136.3 \pm 38}{38}$	Evolocumab 420 mg every 4 weeks	8 weeks	Placebo	Percent change in LDL-C from baseline to week 8

Leiter et al. 2017 / ODYSSEY DM- INSULIN(<u>42</u>)	3b	441	Hypercholesterolemia and insulin-treated patients	62.8 ± 9.5	44.8 ± 66	112 ± 39.8	Alirocumab 75 mg/150 mg every 2 weeks	24 weeks	Placebo	Percent change in LDL-C from baseline to week 24
Lorenzatti et al. 2019 / BERSON(<u>43</u>)	3	981	T2DM and hypercholesterolemia	61.3	69.4± 94	92.8 ± 33.6	Evolocumab 140 mg every 2 weeks or 420 mg every 4 weeks	12 weeks	Placebo	Percent change in LDL-C from baseline to week 12
McKenney et al. 2012(<u>44</u>)	2	183	Hypercholesterolemia on atorvastatin	56.7 ± 10	71.5 ± 111.2	128.5±26.2	Alirocumab 50 mg/100 mg/150 mg every 2 weeks or 200/300 mg every 4 weeks	12 weeks	Placebo	Percent change in LDL-C from baseline to week 12
Moriarty et al. 2015 /ODYSSEY ALTERNATIVE(<u>45</u>)	3	314	Hypercholesterolemia and statin intolerant	63.4 ±9.4	45.9± 57.5	192.3 ± 71.7	Alirocumab 75 mg/150 mg every 2 weeks	24 weeks	Ezetimibe	Percent change in LDL-C from baseline to week 24
Nicholls et al. 2016 / GLAGOV(<u>46</u>)	3	970	Patient on statin and with coronary disease	59.8 ± 9.2	46.8± 76.6	92.5±27.2	Evolocumab 420 mg every 4 weeks	78 weeks	Placebo	Nominal change in percent atheroma volume from baseline to week 78

Nissen et al. 2016 / GAUSS-3(<u>47</u>)	3	218	Statin intolerant patients	58.8 ± 10.5	67.6± 106.5	219.8± 72	Evolocumab 420 mg every 4 weeks	24 weeks	Ezetimibe	Percent change in LDL-C from baseline to week 24
Raal et al. 2012 / RUTHERFORD(<u>48</u>)	2	168	HeFH	50.6 ± 13	72.7 ± 112.6	156.6 ± 39.2	Evolocumab (AMG145) 350mg and 420mg SC every 4 weeks	12 weeks	Placebo	Percentage change in LDL-C at week 12
Raal et al. 2014 / RUTHERFORD- 2(<u>49</u>)	3	331	HeFH	51.2 ± 12.6	93.6± 125.8	156± 44.3	Evolocumab 140 mg every 2 weeks or 420 mg every 4 weeks	12 weeks	Placebo	Percent change in LDL-C from baseline to week 12
Raal et al. 2014 / TESLA Part B(<u>50</u>)	3	50	HoFH	31 ± 13	100.7± 96.6	348 ± 139.2	Evolocumab 420 mg every 4 weeks	12 weeks	Placebo	Percent change in LDL-C from baseline to week 12
Robinson et al. 2014 / LAPLACE-2(<u>51</u>)	3	1899	Hypercholesterolemia on statin	59.8 ± 9.9	68.9±111.3	109 ± 41.6	Evolocumab 140 mg every 2 weeks or 420 mg every 4 weeks	12 weeks	Placebo and/or ezetimibe	Percent change in LDL-C from baseline to week 12

Robinson et al. 2015 / ODYSSEY LONG TERM(<u>52</u>)	3	2341	Hypercholesterolemia on statin and high CV risk	60.5 ± 10.4	65.6± 92	122.4 ± 42.2	Alirocumab 150 mg every 2 weeks	78 weeks	Placebo	Percent change in LDL-C from baseline to week 24
Rosenson et al. 2019 / BANTING(<u>53</u>)	3	421	T2DM and hypercholesterolemia	62.4 ± 8.5	91.8± 115.4	$\begin{array}{c} 109.3 \pm \\ 31.6 \end{array}$	Evolocumab 420 mg every 4 weeks	12 weeks	Placebo	Percent change in LDL-C from baseline to week 12
Roth et al. 2012(<u>54</u>)	2	92	Primary hypercholesterolemia	56.9 ± 9.8	61.2± 87.9	122.6 ± 18.7	Alirocumab 150 mg every 2 weeks	8 weeks	Placebo and/or atorvastatin	Percent change in LDL-C from baseline to week 8
Roth et al. 2014 / ODYSSEY MONO(<u>55</u>)	3	103	Hypercholesterolemia and moderate CV risk	60.2 ± 5	36.9± 48.7	139.7 ± 25.8	Alirocumab 75 mg/150 mg every 2 weeks	24 weeks	Ezetimibe	Percent change in LDL-C from baseline to week 24
Roth et al. 2016 / ODYSSEY CHOICE I(<u>56</u>)	3	803	Hypercholesterolemia and moderate to high CV risk	60.8 ± 10.1	60.2 ± 82.9	125.4± 36.3	Alirocumab 75 mg/150 mg every 2 weeks or 300 mg every 4 weeks	48 weeks	Placebo with or without statin	Percent change in LDL-C from baseline to week 24
Sabatine et al. 2017 / FOURIER(<u>57</u>)	3	27564	Hypercholesterolemia on statin and high CV risk	62.5 ±9	71.7± 112.6	92 (80- 109)	Evolocumab 140 mg every 2 weeks or 420 mg	48 weeks	Placebo	Major cardiovascular events (composite of cardiovascular

							every 4 weeks		death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization)
Schwartz et al. 2018 / ODYSSEY OUTCOMES(58)	3	18924	Hypercholesterolemia after ACS	58.6 ±9.4	60.2 ± 81	92 ± 31	Alirocumab 75 mg to 150 mg 64 months every 2 weeks	Placebo	Composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization
Stein et al. 2012(<u>59</u>)	2	77	HeFH	53.4 ±9.7	135.8± 174.6	146.1 ± 30.1	Alirocumab 150 mg every 2 weeks or 150 mg/200 mg/300 mg every 4 weeks	Placebo	Percent change in LDL-C from baseline to week 12
Stiekema et al. 2018 / ANITSCHKOW(<u>60</u>)	3b	129	Patients \geq 50 years old with fasting LDL- C \geq 100, Lp(a) \geq 125 nmol/L and	60.1	219.4 ± 108.6	145 ± 38.8	Evolocumab 420mg SC 16 weeks monthly	Placebo	Percentage change in MDS TBR of the index vessel

			arterial wall inflammation							at week 16
Stroes et al. 2014 / GAUSS-2(<u>61</u>)	3	307	Statin intolerant patients	61.7 ±9.9	57.6± 94.4	193 ± 58.5	Evolocumab 140 mg every 2 weeks or 420 mg every 4 weeks	12 weeks	Placebo and/or ezetimibe	Percent change in LDL-C from baseline to week 12
Stroes et al. 2016 / ODYSSEY CHOICE II(<u>62</u>)	3	233	Hypercholesterolemia and not on statin	63.1 ± 10.1	40.6± 56.7	158.1± 51.4	Alirocumab 75 mg/150 mg every 2 weeks or 150 mg every 4 weeks	24 weeks	Placebo	Percent change in LDL-C from baseline to week 24
Sullivan et al. 2012 / GAUSS(<u>63</u>)	2	160	Statin intolerant patients due to muscle-related side effects	62.2	73.9± 119.2	188.5± 49.2	Evolocumab 280 mg/350 mg/420 mg every 4 weeks	12 weeks	Placebo and/or ezetimibe	Percent change in LDL-C from baseline to week 12
Teramoto et al. 2016 / ODYSSEY JAPAN(<u>64</u>)	3	216	HeFH or high CV risk	$\begin{array}{c} 60.8 \\ \pm \ 9.5 \end{array}$	40.4± 38	143.1±27.1	Alirocumab 75 mg/150 mg every 2 weeks	52 weeks	Placebo	Percent change in LDL-C from baseline to week 24
Teramoto et al. 2018 / ODYSSEY	3	163	Hypercholesterolemia at low intensity statin	63.6 ±	39.8 ± 41.1	150.9 ± 42.8	Alirocumab 150mg SC every 2	12 weeks	Placebo	Percentage change in LDL-C at

NIPPON(<u>65</u>)			or nonstatin therapy	10.1			weeks or every 4 weeks			week 12
Watts et al. 2017 / NCT02189837(<u>66</u>)	3	81	Healthy normolipidemic patients	31.2	21.3 ± 21.3	117.7± 19.3	Evolocumab 420 mg every 2 weeks	8 weeks	Placebo and/or atorvastatin	Apolipoprotein B kinetics

Data are mean \pm standard deviation or median (interquartile range) unless otherwise stated.

Abbreviations: ACS, acute coronary syndrome; CV, cardiovascular; HeFH, heterozygous familial hypercholesterolemia; HIV, human immunodeficiency virus; HoFH, homozygous familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; Lp(a), Lipoprotein(a); SC, subcutaneous; T2DM, type 2 diabetes mellitus

Table 2:	Summarv on	the	effects	of PCSK9i	on	other l	ipids
10010 2.	Summery on					000000	puis

Lipids	Overall mean percent change	Mean percent change compared to placebo	Mean percent change compared to ezetimibe
			22 2 201
LDL-C	52.41%	-57.51%	-32.23%
	95% CI -55.28 to -49.54%, p<0.001	95% CI -59.53 to -55.49, p<0.001	95% CI -36.36 to -28.1, p<0.001
Non-HDL-C	-46.48%	-50.87%	-28.6%
	95% CI -48.73 to -44.23, p<0.001	95% CI -52.57 to -49.16, p<0.001	(95% CI -31.62 to -25.49, p<0.001)
Total cholesterol	-34.42%	-36.31%	21.47%
	95% CI -36.09 to -32.75, p<0.001	(95% CI -37.68 to -34.94, p<0.001)	(95% CI -25.58 to -17.37, p<0.001)
Triglycerides	-11.11%	-13.27%	-2.05%
	95% CI -12.86 to -9.35, p<0.001	(95% CI -14.84 to -11.70, p<0.001)	(95% CI -4.42 to -0.31, p=0.09)
АроВ	-43.16%	-46.34%	-30.62%
	95% CI -45.32 to -41.00, p<0.001	(95% CI -48.08 to -44.60, p<0.001)	(95% CI -36.0 to -25.15, p<0.001)
Apo-A	4.44%	4.44%	4.64%
	95% CI 3.62 to 5.26, p<0.001	(95% CI 3.62 to 5.26, p<0.001)	(95% CI 2.68 to 6.60, p<0.001)
HDL-C	5.98%	6.19%	4.95%
	95% CI 5.20 to 6.77, p<0.001	(95% CI 5.33 to 7.06, p<0.001)	(95% CI 3.16 to 6.75, p<0.001)

Abbreviations: PCSK9i= proprotein convertase subtisilin/kexin type 9 inhibitors; LDL-C= low density lipoprotein C; non-HDL-C=non-high density lipoprotein C; ApoB = apolipoprotein B; ApoA1 = apolipoprotein A1; HDL-C= high-density lipoprotein C

CENTRAL ILLUSTRATION

Lp (a) reduction of PCSK9i, subgroup analysis and meta-regression

47 eligible RCTs published up to July 2023 analyzed, yielding a total of 67,057 individuals aged ≥ 18 years old who received PCSK9i vs Placebo or Ezetimibe.

Lp (a) Reduction of PCSK9i

Meta-regression: mean changes in LDL-C (A) and Apo-B (B) from intervention on mean change of Lp(a)



A. mean LDL-C change

B. mean Apo-B change





		 y -40 - o 	-60-	0 • •			
baseline Lp(a)	with PCSK9i	-80 -60 -40 -20 Mean LDL-C at follow up	0 -60	-50 -40 -30 -2 Apo-B levels at follow up	20		
mean reduction:-27.0% (95% Cl: -29.8 to -24.1, p<0.00)		LDL-C (p=0.02, tau2 177.1, R2 analog=0.0) Apo-B (p=0.00, tau2=114.2, R=1.4					
Subgroup Analysis		Effects of PCSK9i on other lipid markers					
	<u>P-interaction</u>						
Alirocumab	-29.2%	Lipid	markers	% mean change			
Evolocumab	-24/6%	LDL-C	2	-52.41%			
Placebo	-27.7%	non-H	HDL-C	-46.48%			
Ezetimibe	-24.0%						



PCSK9 - Proprotein convertase subtilisin/kexin type 9; PCK9i - proprotein convertase subtilisin/kexin type 9 inhibitor; RCT - Randomized Control Trial; Lp (a) = Lipoprotein (a); LDL-C = Low density lipoprotein cholesterol; FH = familial hypercholesterolemia; Apo-A = Apolipoprotein A; Apo-B = Apolipoprotein B; TC = total cholesterol; TG: triglycerides; HDL-C = high-density lipoprotein cholesterol; CI = confidence interval

medRxiv preprint doi: https://doi.org/10.1101/2024.07.10.24310245; this version posted July 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv adicense to display the preprint in perpetuity. Study It is made available under a CC-BY-NC-ND 4.0 International stocks are in the preprint of t

Ezetimibe				
Roth et al. (2014) ODDYSSY Mono		-4.40	-14.79, 5.99] 1.48
Bays et al. 2015/ODYSSEY OPTIONS LA		-13.00	-24.64 -1.36	1 1 4 1
Says et al. 2013/00/13321 OF HONSTA		-13.00	-24.04, -1.00	1 4 9 9
Famier et al. (2015) OD FSSET OF HONS II B		-16.90	-30.41, -3.38	1.30
Moriartt et al. (2015)/ODYSSEY ALTERNATIVE		-18.60	-25.39, -11.81] 1.67
Sullivan et al. (2012)/GAUSS		-21.20	-35.86, -6.54] 1.24
Nissen et al. (2016)/GAUSS-3		-21.30	-28.77, -13.83] 1.64
Cannon et al. (2014) ODYSSEY COMBO II	-	-21.70	-26.46 -16.94	1 1.76
Formies et al. (2015) ODVCCEV ODTIONS II A		00.00	25.10, 11.00	1 1 20
Familier et al. (2015) OD FSSET OPTIONS II A		-23.60	-35.52, -11.68	1.39
Stroes et al. (2014)/GAUSS-2 A		-25.30	-34.57, -16.03] 1.55
Stroes et al. (2014)/GAUSS-2 B		-27.90	-40.40, -15.40] 1.36
Bays et al. 2015/ODYSSEY OPTIONS I B		-31.00	-42.10, -19.90	1.44
Han et al. (2019) ODYSSEY EAST	-	-34.30	-39.3529.25	1.75
Has at al. (2022)		49.79	57.67 20.00	1 1 57
Hau et al. (2022)	•	-40.70	-57.07, -59.08	1.5/
Heterogeneity: τ ² = 94.96, I ² = 83.82%, H ² = 6.18	•	-23.98	-29.95, -18.01	1
Test of $\theta_i = \theta_i$: Q(12) = 68.89, p = 0.00				
Test of θ = 0: z = -7.87, p = 0.00				
Placebo				
Bave at al. 2015/ODVSSEV OPTIONS I		-3.401	-14.49 7.60	1 1 4 4
Nickella at al. (2013) OF 13521 OF 110(131	_	-5.40	-14.48, 7.08	1 1.44
Nicholis et al. (2016) GLAGOV	_	-6.80	-8.50, -5.10] 1.84
Koskinas et al. (2019) EVOPACS		-9.90	-23.14, 3.34] 1.32
Raal et al. (2014)/TESLA Part B		-11.80	-25.87, 2.27] 1.27
Stiekerna et al. (2018)/ANITSCHKOW		-13.90	-19.30, -8.50] 1.74
Kereiskes et al. (2015)/ODVSSEV COMBO I		-14.60	-21 27 -7 95	1 1 68
Circhere et al. (0010)		- 14.00		
Ginaberg et al. (2016)		-14.80	-27.21, -2.39	1.37
Kastelein et al. 2015 FH I	-	-17.70	-22.46, -12.94	J 1.76
Koren et al. (2014)/MENDEL II B		-17.80	-45.58, 9.98	0.67
Leiter et al. (2017) ODYSSEY DM-INSULIN A		-18.50	-23.89, -13.11] 1.74
Leiter et al. (2017) ODYSSEV DM-INSULIN P		-18 70	-31.50 -5.9/	1 1 34
Chain at al. (2017) OD 100E 1 Dill-INGOEIN D		-10.50	41.00, 0.00	1 0.00
Stein et al. (2012)		-19.50	-41.03, 2.03	0.89
Robinson et al. (2014)/LAPLACE-2 D		-19.90	-27.98, -11.82] 1.61
Kastelein et al. 2015 FH II		-20.30	-26.40, -14.20] 1.71
Koren et al. (2014)/MENDEL II A		-20.40	-49.86, 9.06	0.62
Schwartz et al. (2018)/ODVSSEV OUTCOMES		-20.40	-91 91 -10 40	1 1 95
Schwarz et al. (2016)/OD 135E1 OD 100MES		-20.40	-21.31, -13.48	1 1.05
Blom et al. 2014/DESCARTES		-22.30	-26.29, -18.31] 1.79
Robinson et al. (2014)/LAPLACE-2 A		-22.40	-30.33, -14.47] 1.62
Janik et al. (2021)		-22.50	-25.55, -19.45] 1.81
Robinson et al. (2014)/LAPLACE-2 H		-24.60	-33.49, -15.71	1 1.57
Bobinson et al. (2015)/ODYSSEY LONG TERM		-25.60	-27.98 -23.22	1 1.83
		20.00	04.75 47.05	1 4 57
Stroes et al. (2016)/ODYSSEY CHOICE II		-25.90	-34.75, -17.05] 1.5/
Sabatine et al. (2017)/FOURIER		-26.60	-27.33, -25.87] 1.85
Boccara et al. (2020)/BEIJERINCK		-27.40	-34.87, -19.93] 1.64
Roth et al. (2016)/ODYSSEY CHOICE I A		-27.70	-35.87, -19.53] 1.61
Bobinson et al. (2014)/I API ACE-2 B		-28.10	-36 75 -19 45	1 1 58
		-20.10	-00.70, -10.40	1 1.00
Robinson et al. (2014)/LAPLACE-2 F		-28.10	-43.55, -12.65	1 1.19
Raal et al. (2014)/RUTHERFORD-2 B		-28.30	-35.78, -20.82] 1.64
Blom et al. 2020/The ODYSSEY HoFH		-28.40	-41.63, -15.17] 1.32
McKenney et al. (2012)		-28.60	-45.56, -11.64] 1.11
Roth et al. (2016)/ODYSSEY CHOICE I B		-29.00	-34.53, -23.47] 1.73
Koren et al. (2012)/MENDEL B		-29 10	-39 24 -18 96	1 1 50
Koren et al. (2012) MENDEL A		-20.10	40.00 40.00	1 4 4 4
Koren et al. (2012)/MENDELA		-29.30	-40.39, -18.21] 1.44
Chao et al. ODYSSEY KT-TW		-30.70	-40.68, -20.72] 1.51
Raal et al. (2012)/RUTHERFORD		-31.50	-40.09, -22.91] 1.58
Robinson et al. (2014)/LAPLACE-2 G		-31.50	-39.81, -23.19] 1.60
Raal et al. (2014)/RUTHERFORD-2 A		-31.60	-39.61, -23.58] 1.61
Robinson et al. (2014)/I API ACE-2 E		-31.80	-43.89 -19.71	1 1.38
Both et al. (2012)		00.00	-54.09 0.07	1 0.07
nouret al. (2012)	-	-32.00	-34.08, -9.92	J U.87
Hobinson et al. (2014)/LAPLACE-2 J		-32.20	-42.52, -21.88	1.49
Hirayama et al. (2014) YUKAWA B		-32.40	-42.25, -22.55] 1.51
Rosenson et al. (2019)/BANTING study		-32.60	-40.28, -24.92] 1.63
Robinson et al. (2014)/LAPLACE-2 C		-33.20	-40.7825.62	1.64
Koh et al. (2018) ODVSSEV KT		03.55	-41.92 -25.96	1 1.60
Wate et al. (2017)		-33.00	-59.40 45.00	1 4 64
watts et al. (2017)		-34.00	-52.40, -15.60	1 1.04
Robinson et al. (2014)/LAPLACE-2 I		-36.40	-43.90, -28.90] 1.64
Ako et al. (2019)/The ODYSSEY J-IVUS	-	-38.60	-45.67, -31.53] 1.66
Teramoto et al. (2016)/ODYSSEY JAPAN	-	-42.00	-48.04, -35.96] 1.71
Lorenzatti et al. 2019 BEARSON B		-45.40	-47.1943.61	1.84
Kivosue et al. (2016)	-	-47.89	-55.72 -40.05	1 1 62
Himuma at al. (2014) VIIVAWA		-47.08	-60.00 40.00	1 4 50
mrayama et al. (2014) YUKAWA A		-50.60	-00.30, -40.90	j 1.52
Teramoto et al. (2018)/ODYSSEY NIPPON		-50.90	-60.23, -41.57] 1.54
Lorenzatti et al. 2019 BEARSON A	_	-62.40	-65.87, -58.93] 1.80
Heterogeneity: τ ² = 115.79, I ² = 96.93%, H ² = 32.57	•	-27.94	-31.14, -24.75]
Test of $\theta = \theta$; Q(52) = 1751.39, n = 0.00	•			
Test of $\theta = 0; z = .17, 14, c = 0.00$		l i i i i i i i i i i i i i i i i i i i		
1000 01 0 = 0. 2 = -17.19, p = 0.00		1		
	▲			
Overall		-27.16	-29.99, -24.33	
Heterogeneity: τ^{z} = 112.58, l^{z} = 96.32%, H^{z} = 27.14				
Test of $\theta_i = \theta_i$: Q(65) = 1820.30, p = 0.00				
Test of $\theta = 0$; z = -18.81, p = 0.00				
Test of group differences: Q _b (1) = 1.31, p = 0.25				

Random-effects REML model Sorted by: _meta_es

-20 Favour PCSK9i Favour Comparator

ò 20

-60 -40



